Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

The latest announcement is out from Nelly Group AB ( ($SE:NELLY) ). Nelly Group AB reported first-quarter 2026 net revenue of SEK 243.3 million, a ...

Nelly Group Posts Margin Gains but Softer Profits Amid CFO Transition in Q1 2026

Traders will find the top stock market stories for Monday in our daily wrap-up.


Morning News Wrap-Up, 4/27/26: Today’s Biggest Stock Market Stories!

Pharmaceutical giant Eli Lilly ($LLY) remains on a buying spree, announcing that it is acquiring cancer drug developer Ajax Therapeutics for $2.3 b...

Eli Lilly (LLY) Continues Buying Spree with $2.3 Billion Purchase of Ajax Therapeutics

SoFi Technologies ($SOFI) is entering what could be its most important earnings moment yet, as the company looks to prove its transition from a los...

SoFi (SOFI) Signals a Real Shift toward Profitability. Now Earnings Need to Confirm It

Last week, stocks pushed to new highs as risk stayed firm and tech led the move. The Dow Jones (DJIA) fell 0.16% to 49,230, while the S&P 500 (SPX)...

The Week That Was, The Week Ahead: Macro and Markets, April 26

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Multicenter, Parallel-Design, Singl...

Eli Lilly’s LY3537031 Renal Study Moves Forward, Shaping Early Pipeline Expectations

Weight-loss drugs could be a big revenue generator.  


Now Is the Time to Buy Hims & Hers Stock (HIMS), Says JPMorgan Chase

The deal involves new weight-loss medications. 


Eli Lilly (LLY) Expands Partnership with Hims & Hers

Shares in tech giant Alphabet ($GOOGL) are only up about 8% year-to-date, with growth tempered by the recent selloff in the elite Magnificent Seven...

Google Cloud Next 2026: Here’s How Alphabet Plans to Fire Up GOOGL Stock with AI

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Johnson & Johnson (JNJ) and Eli Lilly & Co (LLY). ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Eli Lilly & Co (LLY)

In a report released on April 21, Aymeric Poulain from Kepler Capital maintained a Buy rating on Thales, with a price target of €320.00. The compan...

Thales (0IW5) Gets a Buy from Kepler Capital

The pharma giant has a lot of momentum right now. 


Bernstein Pounds the Table on Eli Lilly Stock (LLY) Ahead of Q1 Earnings

In a report released today, from Ord Minnett maintained a Hold rating on CSL, with a price target of A$186.00. In addition to Ord Minnett, CSL also...

CSL (CMXHF) Gets a Hold from Ord Minnett

The pharma giant is diversifying beyond weight-loss medicines. 


UBS Pounds the Table on Eli Lilly Stock (LLY) After Kelonia Therapeutics Deal

The distribution rate is among the highest available to investors. 


Want a Monthly Dividend That Yields 20%? BlackRock (BLK) Has a Fund for You

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Ally Financial (ALLY) and First Financial Bankshare...

Analysts’ Opinions Are Mixed on These Financial Stocks: Ally Financial (ALLY) and First Financial Bankshares (FFIN)

TipRanks is home to the hottest stock market stories traders need to know about on Monday.


Morning News Wrap-Up, 4/20/26: Today’s Biggest Stock Market Stories!

The deal is expected to close by the end of June this year. 


M&A News: Eli Lilly (LLY) Announces Blockbuster $7 Billion Acquisition of Kelonia Therapeutics

Eli Lilly stock gained after the pharmaceutical company announced a $3.25B deal for Kelonia Therapeutics.


Eli Lilly Stock (LLY) Investors Need to Know About a New $3.25B Deal

There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Ally Financial (ALLY), Private Bancorp of America (PB...

Wall Street Analysts Are Bullish on Top Financial Picks

Last week, stocks moved higher across the board as risk eased and oil prices fell. The Dow Jones (DJIA) rose 1.79% to 49,447, while the S&P 500 (SP...

The Week That Was, The Week Ahead: Macro and Markets, April 19

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. is running an early study of its new drug LY429...

Lilly’s New Autoimmune Candidate LY4298445 Moves Through Early Testing

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) has completed a Phase 3 study titled “A P...

Eli Lilly’s Oral Orforglipron Study Completion Signals Next Step in Diabetes and Obesity Market Race

April is shaping up as a month where investors are looking for exposure to sectors that can outperform in different macro environments. ETFs are a ...

2 Best ETFs to Buy in April 2026, According to Analysts

Kailera Therapeutics’ ($KLRA) shares soared as high as 68% on Friday following its debut on Nasdaq, with the obesity treatment developer raising $6...

Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market

The U.S. Federal Aviation Administration is working with several companies to develop a new artificial intelligence tool for managing air traffic. ...

Palantir Eyes Major FAA Deal to Modernize Air Traffic

Traders will find the hottest stock market happenings on Friday in our daily wrap-up.


Morning News Wrap-Up, 4/17/26: Today’s Biggest Stock Market Stories!

The company is locked in a battle with rival Novo Nordisk. 


Eli Lilly’s (LLY) Weight-Loss Pill Prescribed Nearly 1,400 Times in First Week

Trader seeking the latest stock market stories will find them in the TipRanks daily wrap-up.


Morning News Wrap-Up, 4/16/26: Today’s Biggest Stock Market Stories!

Barclays analyst Milene Kerner maintained a Sell rating on Thales on April 14 and set a price target of €270.00. The company’s shares closed last T...

Barclays Keeps Their Sell Rating on Thales (0IW5)

BMO Capital Markets ($BMO) is pounding the table on Eli Lilly’s ($LLY) stock as the pharmaceutical giant launches its new weight-loss pill. reitera...

Eli Lilly Stock (LLY) Gets Another Buy Rating as Its Obesity Pill Hits the Market

Traders seeking the latest stock market stories will find them in our daily roundup.


Morning News Wrap-Up 4/13/26: Today’s Biggest Stock Market Stories!

Eli Lilly ($LLY) announced that it has made significant progress with a new leukemia drug, giving its stock a shot in the arm as a result. The phar...

Eli Lilly Stock (LLY) Gets Shot in the Arm from New Leukemia Drug

Ord Minnett analyst maintained a Hold rating on CSL today and set a price target of A$198.00. In addition to Ord Minnett, CSL also received a Hold ...

Ord Minnett Sticks to Its Hold Rating for CSL (CMXHF)

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on National Australia Bank Limited (NAUBF) and Ally Fina...

Analysts Are Bullish on These Financial Stocks: National Australia Bank Limited (NAUBF), Ally Financial (ALLY)

India is known as the ‘world’s pharmacy’


Eli Lilly’s (LLY) Market Share in India Dips as Weight-Loss Drug War Heats Up

In a report released on April 8, Aymeric Poulain from Kepler Capital maintained a Buy rating on Thales, with a price target of €320.00. The company...

Kepler Capital  Reaffirms Their Buy Rating on Thales (0IW5)

In a report released yesterday, Steven Wheen from Jarden maintained a Buy rating on CSL, with a price target of A$270.00. The company’s shares clos...

Jarden Sticks to Its Buy Rating for CSL (CMXHF)

Traders looking for the hottest stock market stories will find them in our daily wrap-up.


Morning News Wrap-Up 4/9/26: Today’s Biggest Stock Market Stories!

The tech giant has shipped weight-loss drugs since 2021. 


Amazon Offers Same-Day Delivery of Eli Lilly’s (LLY) Weight-Loss Pill

Owning the entire market is viewed as a safe investing strategy. 


XLV, VHT, IXJ: Invest in the Healthcare Sector with Exchange-Traded Funds

An update from Holley ( ($HLLY) ) is now available. Holley Inc. announced that Executive Vice President, General Counsel and Corporate Secretary Ca...

Holley Announces Executive Vice President and General Counsel Exit

The obesity medication is forecast to be a bestseller.


Eli Lilly (LLY) CEO Says Company Ready to Scale Production of Weight-Loss Pill

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and P...

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 1 trial “A Study of LY4060874 in Healthy Participants” ...

Eli Lilly’s LY4060874 Phase 1 Readout: What a Quiet Pipeline Update Means for LLY Investors

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Structure Therapeutics, Inc. Sponsored ADR (GPCR) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvation Bio (NUVB) and Eli Lilly & Co (LLY) with bu...

Shares in Danish drugmaking giant Novo Nordisk ($NVO) — already down about 26% since the start of the year — are now facing even more pressure afte...

Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly (LLY) Challenge

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Merit Medical Systems (MMSI...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Merit Medical Systems (MMSI)

The regulatory clearance has arrived sooner than expected. 


Eli Lilly Stock (LLY) Surges as FDA Approves Weight-Loss Pill

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Definium Therapeutics (DFTX) and Eli Lilly & Co (LLY...

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Eli Lilly & Co (LLY)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,280.00. Bansal covers the Healthcare ...

Eli Lilly & Co (LLY) Gets a Buy from Wells Fargo

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY) and Houlihan Lokey (HLI). Ally Financial (AL...

Analysts Offer Insights on Financial Companies: Ally Financial (ALLY) and Houlihan Lokey (HLI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Centene (CNC), Eli Lilly & Co (LLY) and Gilead Scien...

Analysts’ Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)

The latest stock market stories for Tuesday are ready to go in the daily wrap-up.


Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!

The pharma giant is making a big push into China. 


Current Quarter	$7.44	Next Quarter	$8.41
Current Year	$33.9	Next Year	$42.07
QoQ Growth	+13.0%	YoY Growth	+24.1%
3Y EPS CAGR	+49.2%	Target Price	$1240.89
Consensus	Buy	Upside	+42.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$874.00	+0.66%	2.56M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$874.00	+0.7%	2.56M
3
4
5
6

LLY

LLY

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel